Clinical Manifestations, Mutational Analysis, and Immunological Phenotype in Patients with RAG1/2 Mutations: First Cases Series from Mexico and Description of Two Novel Mutations.


Journal

Journal of clinical immunology
ISSN: 1573-2592
Titre abrégé: J Clin Immunol
Pays: Netherlands
ID NLM: 8102137

Informations de publication

Date de publication:
08 2021
Historique:
received: 03 02 2021
accepted: 20 04 2021
pubmed: 7 5 2021
medline: 4 2 2022
entrez: 6 5 2021
Statut: ppublish

Résumé

Mutations in recombinase activating genes 1 and 2 (RAG1/2) result in human severe combined immunodeficiency (SCID). The products of these genes are essential for V(D)J rearrangement of the antigen receptors during lymphocyte development. Mutations resulting in null-recombination activity in RAG1 or RAG2 are associated with the most severe clinical and immunological phenotypes, whereas patients with hypomorphic mutations may develop leaky SCID, including Omenn syndrome (OS). A group of previously unrecognized clinical phenotypes associated with granulomata and/or autoimmunity have been described as a consequence of hypomorphic mutations. Here, we present six patients from unrelated families with missense variants in RAG1 or RAG2. Phenotypes observed in these patients ranged from OS to severe mycobacterial infections and granulomatous disease. Moreover, we report the first evidence of two variants that had not been associated with immunodeficiency. This study represents the first case series of RAG1- or RAG2-deficient patients from Mexico and Latin America.

Identifiants

pubmed: 33954879
doi: 10.1007/s10875-021-01052-0
pii: 10.1007/s10875-021-01052-0
pmc: PMC8319791
mid: NIHMS1727328
doi:

Substances chimiques

DNA-Binding Proteins 0
Homeodomain Proteins 0
Nuclear Proteins 0
RAG2 protein, human 0
RAG-1 protein 128559-51-3

Types de publication

Case Reports Journal Article Research Support, N.I.H., Intramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1291-1302

Subventions

Organisme : Intramural NIH HHS
ID : ZIA AI001222
Pays : United States

Commentaires et corrections

Type : ErratumIn

Informations de copyright

© 2021. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.

Références

Database (Oxford). 2019 Jan 1;2019:
pubmed: 30722040
Nucleic Acids Res. 2000 Jan 1;28(1):235-42
pubmed: 10592235
Blood. 2014 Jan 9;123(2):281-9
pubmed: 24144642
Acta Biomed. 2011 Apr;82(1):5-13
pubmed: 22069950
Genes Dev. 2016 Apr 15;30(8):909-17
pubmed: 27056670
Hum Mutat. 2006 Dec;27(12):1174-84
pubmed: 16960852
J Clin Invest. 2018 Jul 2;128(7):3071-3087
pubmed: 29889099
Nat Rev Immunol. 2016 Apr;16(4):234-46
pubmed: 26996199
J Clin Immunol. 2020 Jan;40(1):24-64
pubmed: 31953710
Blood. 2002 Sep 15;100(6):2145-52
pubmed: 12200379
J Mol Graph. 1996 Feb;14(1):33-8, 27-8
pubmed: 8744570
Immunol Rev. 2019 Jan;287(1):73-90
pubmed: 30565244
J Allergy Clin Immunol. 2018 Jun;141(6):2303-2306
pubmed: 29477728
Sci Rep. 2017 Sep 5;7(1):10480
pubmed: 28874689
Clin Genet. 2004 Apr;65(4):322-6
pubmed: 15025726
Nucleic Acids Res. 2001 Jan 1;29(1):308-11
pubmed: 11125122
Clin Exp Immunol. 2019 Feb;195(2):202-212
pubmed: 30307608
BMC Bioinformatics. 2006 Aug 16;7:382
pubmed: 16914055
Nat Struct Mol Biol. 2020 Feb;27(2):119-126
pubmed: 32015552
Mol Cell Biol. 2000 Aug;20(15):5653-64
pubmed: 10891502
Mol Cell. 2018 Apr 19;70(2):358-370.e4
pubmed: 29628308
Front Immunol. 2018 Aug 08;9:1837
pubmed: 30147696
J Clin Immunol. 2014 Oct;34(7):792-5
pubmed: 25104208
Nature. 2020 May;581(7809):434-443
pubmed: 32461654
Science. 1996 Oct 4;274(5284):97-9
pubmed: 8810255
Arch Biochem Biophys. 2016 Dec 1;611:3-19
pubmed: 27117234
Proteins. 2003 Feb 15;50(3):437-50
pubmed: 12557186
J Chem Theory Comput. 2016 Jan 12;12(1):405-13
pubmed: 26631602
J Allergy Clin Immunol. 2014 Apr;133(4):1099-108
pubmed: 24290284
Cell. 2015 Nov 19;163(5):1138-1152
pubmed: 26548953
N Engl J Med. 2008 May 8;358(19):2030-8
pubmed: 18463379
J Mol Biol. 2020 Jun 26;432(14):4127-4138
pubmed: 32450081
Nucleic Acids Res. 2012 Jul;40(Web Server issue):W452-7
pubmed: 22689647
Nat Struct Mol Biol. 2018 Aug;25(8):732-742
pubmed: 30061602
J Comput Chem. 2009 Jul 30;30(10):1545-614
pubmed: 19444816
J Comput Chem. 2008 Aug;29(11):1859-65
pubmed: 18351591
Clin Dev Immunol. 2012;2012:261470
pubmed: 23243423
J Clin Immunol. 2018 Aug;38(6):646-655
pubmed: 30046960
Genet Med. 2015 May;17(5):405-24
pubmed: 25741868
Nat Struct Mol Biol. 2020 Feb;27(2):127-133
pubmed: 32015553
Clin Exp Immunol. 2000 Nov;122(2):143-9
pubmed: 11091267
Nucleic Acids Res. 1998 Jan 1;26(1):285-7
pubmed: 9399854
Blood. 2001 Jan 1;97(1):81-8
pubmed: 11133745
PLoS One. 2015 Feb 03;10(2):e0117380
pubmed: 25647319
Protein Sci. 2020 Jan;29(1):111-119
pubmed: 31606900
Proc Natl Acad Sci U S A. 2007 Nov 27;104(48):18993-8
pubmed: 18025461
Curr Opin Allergy Clin Immunol. 2020 Dec;20(6):574-581
pubmed: 33044342
Iran J Allergy Asthma Immunol. 2011 Jun;10(2):129-32
pubmed: 21625022
Am J Hum Genet. 2016 Oct 6;99(4):877-885
pubmed: 27666373
J Mol Biol. 2019 May 17;431(11):2197-2212
pubmed: 30995449
J Chem Inf Model. 2020 Jun 22;60(6):3315-3323
pubmed: 32401507
Nature. 2019 May;569(7754):79-84
pubmed: 30971819
Front Immunol. 2017 Jul 12;8:808
pubmed: 28747913
Blood. 2001 May 1;97(9):2772-6
pubmed: 11313270
J Biol Chem. 2000 Apr 28;275(17):12672-5
pubmed: 10777560
Nat Methods. 2010 Apr;7(4):248-9
pubmed: 20354512
Blood. 2010 Aug 26;116(8):1263-71
pubmed: 20489056
J Allergy Clin Immunol. 2019 Jan;143(1):405-407
pubmed: 30193840
Proteins. 1992 Oct;14(2):309-23
pubmed: 1409577
PLoS Comput Biol. 2014 Jan;10(1):e1003440
pubmed: 24453961
J Allergy Clin Immunol Pract. 2019 Jul - Aug;7(6):1970-1985.e4
pubmed: 30877075
Nature. 2015 Feb 26;518(7540):507-11
pubmed: 25707801
Front Pediatr. 2019 Apr 16;7:122
pubmed: 31058115
Ital J Pediatr. 2012 Mar 16;38:8
pubmed: 22424479
Nucleic Acids Res. 2020 Apr 17;48(7):3553-3566
pubmed: 32086526
J Allergy Clin Immunol. 2016 Jun;137(6):1780-1787
pubmed: 26915675
Mol Cell. 2009 Jun 12;34(5):535-44
pubmed: 19524534
BMC Med Genet. 2009 Nov 13;10:116
pubmed: 19912631

Auteurs

Saul Oswaldo Lugo-Reyes (SO)

Laboratorio de Inmunodeficiencias, Instituto Nacional de Pediatría, Mexico City, Mexico.

Nina Pastor (N)

Centro de Investigación en Dinámica Celular, Universidad Autónoma del Estado de Morelos, Cuernavaca, Mexico.

Edith González-Serrano (E)

Laboratorio de Inmunodeficiencias, Instituto Nacional de Pediatría, Mexico City, Mexico.

Marco Antonio Yamazaki-Nakashimada (MA)

Laboratorio de Inmunodeficiencias, Instituto Nacional de Pediatría, Mexico City, Mexico.

Selma Scheffler-Mendoza (S)

Laboratorio de Inmunodeficiencias, Instituto Nacional de Pediatría, Mexico City, Mexico.

Laura Berron-Ruiz (L)

Laboratorio de Inmunodeficiencias, Instituto Nacional de Pediatría, Mexico City, Mexico.

Guillermo Wakida (G)

Laboratorio de Inmunodeficiencias, Instituto Nacional de Pediatría, Mexico City, Mexico.

Maria Enriqueta Nuñez-Nuñez (ME)

Hospital Civil de Guadalajara Dr. Juan I. Menchaca, Guadalajara, Mexico.

Ana Paola Macias-Robles (AP)

Centro Medico Nacional de Oriente IMSS, Mexico City, Mexico.

Aide Tamara Staines-Boone (AT)

Unidad Médica de Alta Especialidad 25, Instituto Mexicano del Seguro Social, Mexico City, Mexico.

Edna Venegas-Montoya (E)

Unidad Médica de Alta Especialidad 25, Instituto Mexicano del Seguro Social, Mexico City, Mexico.

Carmen Alaez-Verson (C)

Instituto Nacional de Medicina Genómica, Mexico City, Mexico.

Carolina Molina-Garay (C)

Instituto Nacional de Medicina Genómica, Mexico City, Mexico.

Luis Leonardo Flores-Lagunes (LL)

Instituto Nacional de Medicina Genómica, Mexico City, Mexico.

Karol Carrillo-Sanchez (K)

Instituto Nacional de Medicina Genómica, Mexico City, Mexico.

Julie Niemela (J)

Laboratory of Clinical Immunology and Microbiology, National Institute of Health, Mexico City, Mexico.

Sergio D Rosenzweig (SD)

Laboratory of Clinical Immunology and Microbiology, National Institute of Health, Mexico City, Mexico.

Paul Gaytan (P)

Instituto de Biotecnología, Universidad Nacional Autónoma de México, Mexico City, Mexico.

Jorge A Yañez (JA)

Instituto de Biotecnología, Universidad Nacional Autónoma de México, Mexico City, Mexico.

Ivan Martinez-Duncker (I)

Centro de Investigación en Dinámica Celular, Universidad Autónoma del Estado de Morelos, Cuernavaca, Mexico.

Luigi D Notarangelo (LD)

Laboratory of Clinical Immunology and Microbiology, National Institute of Health, Mexico City, Mexico.

Sara Espinosa-Padilla (S)

Laboratorio de Inmunodeficiencias, Instituto Nacional de Pediatría, Mexico City, Mexico. saraelvaespino@gmail.com.

Mario Ernesto Cruz-Munoz (ME)

Facultad de Medicina, Universidad Autónoma del Estado de Morelos, Cuernavaca, Mexico. mario.cruz@uaem.mx.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH